Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40
-0.5400-6.04%
Post-market: 8.500.1000+1.19%19:16 EDT
Volume:1.39M
Turnover:12.03M
Market Cap:262.84M
PE:-2.95
High:9.25
Open:8.90
Low:8.40
Close:8.94
52wk High:50.40
52wk Low:8.40
Shares:31.29M
Float Shares:15.69M
Volume Ratio:0.67
T/O Rate:8.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8500
EPS(LYR):-2.8503
ROE:-33.63%
ROA:-21.86%
PB:0.92
PE(LYR):-2.95

Loading ...

Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Dow Jones
·
Mar 26

Silexion Therapeutics Announces Immediate Board Membership Change

TIPRANKS
·
Mar 26

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
Mar 26

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Dow Jones
·
Mar 26

Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy

TIPRANKS
·
Mar 26

Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative

Simply Wall St.
·
Mar 26

Damora Therapeutics Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Mar 26

Clear Street sees buying opportunity for Beam Therapeutics after study update

TIPRANKS
·
Mar 26

Denali Therapeutics granted FDA approval of AVLAYAH for treatment of MPS II

TIPRANKS
·
Mar 25

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

GlobeNewswire
·
Mar 25

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Mar 25

NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 25

Travere Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 25

Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels

Benzinga
·
Mar 25

CORRECTION: Enlivex Therapeutics Q4 Adj. EPS $(0.20) Misses $(0.01) Estimate. Adj EPS Excludes Change In Fair Value Of Digital Assets Purchase Option

Benzinga
·
Mar 25

Enlivex Therapeutics Q4 EPS $26.83 Beats $(0.13) Estimate

Benzinga
·
Mar 25

B. Riley Raises Price Target on Lineage Cell Therapeutics to $4 From $3, Keeps Buy Rating

MT Newswires Live
·
Mar 25

Travere Therapeutics price target lowered to $41 from $44 at JPMorgan

TIPRANKS
·
Mar 25

Avalo Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Avalo Therapeutics price target raised to $40 from $25 at H.C. Wainwright

TIPRANKS
·
Mar 25